Targeting the GABA-modulator microbiota against the progression of CNS inflammatory demyelination
Targeting the GABA-modulator microbiota against the progression of CNS inflammatory demyelination
批准号:
10729124
负责人:
Javier Ochoa-Reparaz
金额:
$7.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-10-20 至 2024-03-31
中文摘要
项目总结
血清神经递质抑制物γ-氨基丁酸(GABA)水平降低
患有进行性多发性硬化症(MS)的患者,初步证据表明肠道
与健康的人相比,GABA水平也会降低。肠道细菌在GABA中起作用
和L-谷氨酸,新陈代谢。GABA是一种抑制性神经递质,也是胃肠道的关键调节因子
肌束功能和谷氨酸是一种兴奋性神经递质。几类细菌,包括乳酸
细菌合成谷氨酸或含有催化合成谷氨酸脱羧酶(GAD)的酶
对GABA的影响。由于它们调节GABA/谷氨酸水平的作用,肠道微生物可以成为靶标
GABA能,抑制性,效果。我们的初步数据显示,疾病本身就改变了
实验性自身免疫性脑脊髓炎(EAE)小鼠的微生物区系,研究MS的模型等,
归类为乳酸菌的细菌分类群,包含与免疫调节作用有关的物种
在患病小鼠的肠道中减少。我们认为肠道微生物区系及其对全身和全身的影响
神经GABA代谢是多发性硬化症临床过渡的关键因素
假设,1)观察到的免疫/炎症反应增强的患者
经历过急性炎症性多发性硬化症增加肠道屏障通透性;2)这扰乱了
减少产生GABA的微生物的数量;3)肠道和全身的减少
GABA浓度升高,导致中枢神经系统免疫/炎症反应增强
中枢神经系统(CNS)和肠道,导致微生物区系和GABA进一步失衡。为了
验证我们的假设,我们建议在实验性EAE疾病(C57BL/6模型)中确定
髓鞘少突胶质细胞糖蛋白35-55,MOG35-55),GABA补充是否使用遗传
设计用于表达GAD(GAD-L)额外拷贝的工程益生菌乳酸菌)会减少炎症
通过促进免疫调节(目标1),降低肠道屏障通透性(目标2)并最终改善
疾病进展(目标3)。我们预计,以EAE中GABA水平为目标将减少
肠道和全身炎症,肠道通透性和细菌易位,并将恢复
肠道微生物区系的组成。我们预测,结果将是对
疾病的进展,与肠道和全身的GABA水平升高有关。我们的
针对微生物区系的研究方法尚未尝试,强调了创新和
我们项目的新颖性可能会给女士的治疗带来革命性的变化,我们的方法是专门为
为本科生和研究生提供为神经免疫学项目做出贡献的机会
重点放在肠道/脑轴上。
英文摘要
PROJECT SUMMARY
Reduced serum levels of the inhibitor neurotransmitter gamma-aminobutyric acid (GABA) are found in
patients suffering from progressive multiple sclerosis (MS), and preliminary evidence suggests that intestinal
GABA levels are also reduced when compared to healthy individuals. Intestinal bacteria play a role in GABA
and L-Glutamate, metabolism. GABA is an inhibitory neurotransmitter and key regulator of the gastrointestinal
tract function and Glu is an excitatory neurotransmitter. Several groups of bacteria, including lactic acid
bacteria synthesize Glu or harbor the enzyme glutamic acid decarboxylase (GAD) that catalyzes the synthesis
of GABA. Because of their role modulating GABA/Glutamate levels, intestinal microbes can be targeted for
GABAergic, inhibitory, effects. Our preliminary data show that disease, alone, alters the composition of the
microbiota of experimental autoimmune encephalomyelitis (EAE) mice, a model to study MS. Among others,
bacteria taxa grouped as lactic acid bacteria that contain species associated with immunomodulatory roles
were reduced in the gut of diseased mice. We propose that the gut microbiota and its impact on systemic and
neural GABA metabolism are key contributing factors to the clinical transition to the progression of MS. We
hypothesize that, 1) the heightened immune/inflammatory response observed in patients who have
experienced acute inflammatory MS increases intestinal barrier permeability; 2) this disrupts the composition of
the microbiome to reduce the number of GABA-producing microbes; 3) Decreases in intestinal and systemic
GABA concentrations follow, leading to, 4) enhanced immune/inflammatory response in the central nervous
system (CNS) and the gut, resulting in additional further imbalances of both microbiota and GABA. In order to
test our hypotheses, we propose to determine in the experimental EAE disease (C57BL/6 model induced with
myelin oligodendrocyte glycoprotein 35-55, MOG35-55), whether GABA supplementation using a genetically
engineered probiotic designed to express additional copies of GAD (GAD-L. lactis) will decrease inflammation
by promoting immunomodulation (Aim 1), reduce intestinal barrier permeability (Aim 2) and ultimately improve
disease progression (Aim 3). We anticipate that targeting GABA levels in EAE will reduce the extent of
intestinal and systemic inflammation, intestinal permeability and bacterial translocation and will restore the
composition of the intestinal microbiota. We predict that the outcome will be the protection against the
progression of the disease, associated with enhanced levels of GABA both intestinal and systemically. Our
research approach targeting the microbiota has not yet been attempted, underscoring the innovation and
novelty of our project that could revolutionize therapeutics for MS. Our approach was designed specifically to
offer undergraduate and graduate students the opportunity to contribute on a neuroimmunology project that
focuses on the gut/brain axis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effects of sex-dependent susceptibility to CNS inflammatory demyelination on the intestinal mucosa
-
批准号:10731325
-
项目类别:
-
资助金额:$14.05万
-
财政年份:2022
-
负责人:Javier Ochoa-Reparaz
-
依托单位:
Effects of sex-dependent susceptibility to CNS inflammatory demyelination on the intestinal mucosa
-
批准号:10755640
-
项目类别:
-
资助金额:$16.15万
-
财政年份:2014
-
负责人:Javier Ochoa-Reparaz
-
依托单位:
国内基金
海外基金
登录
查看更多内容
脑胶质母细胞瘤中SLC1A3⁺小胶质细胞通过Glu-GABA代谢失衡诱导T细胞耗竭的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:崔舒
-
依托单位:
基于GABA受体抑制剂Nicofluprole的新型杀虫剂创制与构效关系
-
批准号:32603872
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2026
-
负责人:刘东东
-
依托单位:
基于GABA能神经环路探讨乌藤疏肝丸重塑神经兴奋-抑制平衡的抗抑郁机制
-
批准号:2026JJ30174
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘晓亭
-
依托单位:
从肝失疏泄探讨肝脏代谢物介导IL-6/STAT3通路调控GABA能系统对睡眠节律影响的机制及逍遥散的干预作用
-
批准号:2026JJ30175
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:滕永杰
-
依托单位:
背根神经节GABA重摄取改变在神经痛中的作用及其机制研究
-
批准号:JCZRLH202600149
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
新型智能氧递送体系介导小胶质细胞极化-GABA能神经元互作治疗脊髓损伤后神经源性膀胱的机制研究
-
批准号:82503085
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:肖玉红
-
依托单位:
GABA诱导小胶质细胞分泌Ccl2介导Treg细胞入脑的肺癌脑转移机制研究
-
批准号:82503497
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:王睿
-
依托单位:
神经递质GABA调控肝脏代谢的分子机制和功能
-
批准号:32530048
-
项目类别:重点项目
-
资助金额:218.00万元
-
批准年份:2025
-
负责人:杜文静
-
依托单位:
糖基化α-Dystroglycan重塑GABA能突触连接在慢性应激所致认知损伤中的作用及机制研究
-
批准号:JCZRQN202500537
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
肠道谷氨酸代谢异常与额顶网络
Glu/GABA失衡介导抑郁症认知损害的肠-
脑关联研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:黄园园
-
依托单位: